Rivean Capital has acquired a majority stake in Acture Group from IK Partners

IK Partners

Rivean Capital (“Rivean”) is pleased to announce that it has signed a definitive agreement to acquire a majority stake in Acture Group (“Acture” or “the Group”), a leading provider of holistic employee welfare solutions, from IK Partners (“IK”). The stake is being acquired from the IK Small Cap II (“IK SC II”) Fund, with Co-Founder and current CEO Maudie Derks, as well as the management team, reinvesting alongside Rivean.

Founded in 2008 and headquartered in Nijmegen, the Netherlands, Acture is a specialised outsourced service provider supporting corporates and staffing agencies in managing employee absence. The Group has an integrated approach to employee welfare, offering complementary services such as absence management and reduction, including case management and reintegration programmes, combined with an absence insurance proposition.

Acture’s heritage and longstanding experience as a pioneer in the private social security services market in the Netherlands have resulted in large amounts of valuable data being translated into innovative case management solutions supported by proprietary technology. With IK’s support since 2020, the Group completed four add-on acquisitions in the Netherlands and three in Germany, to further complement its proposition and expand its geographical footprint. Acture is also currently rolling out a mental health absence management platform, Evermood, in the Netherlands and the DACH region. Through its full-service offering, Acture is well positioned to fully unburden customers who are confronted with labour market shortages and rising absenteeism costs. At present, the Group employs approximately 390 full-time employees across its offices in the Netherlands and Germany.

Ready for the next phase of growth

The Group’s ambition to reinforce its position as a leading European provider of specialised outsourced services and insurance products requires further investment in the organisation to help develop its digital offering and platform capabilities. With Rivean’s support, Acture will continue along its international growth trajectory, accelerating the execution of its strategic growth plan and transforming from a leading Dutch player in the social security market, to a European total employee welfare platform.

Maudie Derks, CEO of Acture, said: “With the recent add-on acquisitions, Acture has taken its first steps into the international arena while simultaneously expanding its offering with a tech-driven wellbeing proposition. Through the new partnership with Rivean, we plan to accelerate our international roll-out, advance our ambitious growth trajectory and further develop the total employee welfare management concept. We would like to thank IK for their support over the past few years and look forward to joining forces with Rivean.”

Nikolai Pronk, Managing Partner at Rivean Capital, commented: “We are very impressed by Acture’s leading market position, supporting its customers with an integrated offering and with a track record of consistent growth. We look forward to partnering with Maudie and the management team to support Acture in its next development and international growth phase.”

Sander van Vreumingen, Partner at IK and Advisor to the IK SC II Fund, added: “Over the past four years, we have had the pleasure of working very closely with Maudie and her team. From the start, we have been impressed with the combined professionalism and expertise of the team, which has enabled both the successful implementation of multiple organic growth initiatives and execution of several bolt-on acquisitions. We are proud of all that we have achieved in partnership with Acture and would like to wish Maudie and her team all the very best in the next stage of their journey.”

Completion of the transaction is subject to obtaining merger clearance, AFM and works council approval.

For further questions, please contact:

Rivean Capital
Maikel Wieland
Partner – Head of Investor Relations & Co-Investments
Phone: +41 43 268 20 30
m.wieland@riveancapital.com

IK Partners
Vidya Verlkumar
Head of Communications and Marketing
Phone: +44 7787 558 193
vidya.verlkumar@ikpartners.com

About Rivean Capital

Rivean Capital (“Rivean”) is a leading European private equity investor for mid-market transactions,
active in the DACH region, the Benelux countries, and Italy. Funds advised by Rivean Capital manage
over EUR 5 billion in assets. Since its inception in 1982, Rivean has supported more than 250
companies in realizing their growth ambitions and has a strong track record of supporting and scaling
successful high-tech businesses with cross-border growth agendas, including footprint expansions and
operational excellence trajectories. Headquartered in Amsterdam, Netherlands, Rivean Capital also has
offices in Brussels, Frankfurt/Main, Milan, and Zug, enabling a strong local presence across key
European markets. For more information, visit riveancapital.com

Read More

About IK Partners

IK Partners (“IK”) is a European private equity firm focused on investments in the Benelux, DACH,
France, Nordics and the UK. Since 1989, IK has raised more than €17 billion of capital and invested in
over 195 European companies. IK supports companies with strong underlying potential, partnering with
management teams and investors to create robust, well-positioned businesses with excellent long-term
prospects. For more information, visit ikpartners.com

Categories: News

Tags:

Mayapada Healthcare Group Secures $157 Million Strategic Growth Investment from Bain Capital

BainCapital

Source: Mayapada Healthcare Group

Partnership Enables Mayapada Healthcare Group to Drive Innovation, Expand Reach, and Meet Indonesia’s Growing Healthcare Demand

Jakarta – December 12, 2024 – Mayapada Healthcare Group, a leading private premium healthcare provider specializing in multi-disciplinary and specialty care, announced a $157 million strategic growth investment from Bain Capital, a global private investment firm. It demonstrates strong confidence in Mayapada Hospital’s premium healthcare platform, which is well-positioned to meet the growing demand for high-quality care in Indonesia.

The investment be used to further scale access Mayapada Healthcare Group’s hospital platform through organic and strategic growth initiatives.  It will also support its mission to address Indonesia’s increasing demand for high-quality healthcare services, ultimately improving patient outcomes nationwide. This strategic partnership with Mayapada Healthcare Group aligns with Bain Capital’s global expertise in adding value to healthcare providers, including APMG, Estia Health, Grupo NotreDame Intermedica, HCA, and Nichii Gakken.

Founded in 2008, Mayapada Healthcare Group operates a growing network of premium hospitals to meet Indonesia’s increasing demand for high-quality healthcare. With seven hospitals across Indonesia, including a flagship hospital in Jakarta Selatan, the company serves a large part of the nation’s population and particularly in the densely populated island of Java. It prioritizes patient-centric care supported by advanced technology, specialized medical teams, and sustainable practices. Mayapada Healthcare Group has steadily expanded its footprint, adding five hospitals between 2018 and 2024, and currently has a substantial pipeline of brown and greenfield expansion. Committed to improving access to reliable healthcare, the organization continuously develops its facilities to address community needs, delivering safe, high-quality medical services to Indonesians.

“Indonesia faces a growing gap between healthcare supply and demand due to demographic shifts like an aging population and rising affluence,” said Jonathan Tahir, Chairman and Group CEO of Mayapada Healthcare Group. “Mayapada Healthcare Group is dedicated to making reliable, high-quality healthcare accessible to all Indonesians,” Tahir emphasized. “By leveraging technology and empowering our specialists, we aim to improve patient outcomes and set a new standard for innovative healthcare.”

“Bain Capital brings not just resources, but also deep expertise in helping healthcare providers thrive in a rapidly evolving ecosystem. We are excited for this partnership, which is rooted in a shared vision for what healthcare can achieve in Indonesia, ” Tahir concluded.

“Bain Capital is thrilled to partner with Mayapada Healthcare Group, whose mission and growth strategy align well with the evolving needs of Indonesia’s healthcare market,” said Sarit Chopra, Partner and Head of Special Situations, Asia at Bain Capital.  “As the private healthcare market in Indonesia is just beginning to develop, we have deep conviction that Mayapada has already built a strong foundation for continued growth. We’re committed to enhancing it with top talent, systems, and technology and we are eager to apply our global expertise to support Mayapada’s next growth phase.”

The investment was made through Bain Capital’s Special Situations strategy, which oversees over $20bn AUM and has invested $35bn since its inception.

The transaction is subject to regulatory and public shareholders approval, with targeted closing in early 2025.

###

About Bain Capital

Bain Capital, LP is one of the world’s leading private investment firms that creates lasting impact for our investors, teams, businesses, and the communities in which we live. Since our founding in 1984, we’ve applied our insight and experience to organically expand into numerous asset classes including private equity, credit, public equity, venture capital, real estate, life sciences, insurance, and other strategic areas of focus. The firm has offices on four continents, more than 1,850 employees, and approximately $185 billion in assets under management.  Bain Capital’s Special Situations strategy offers tailored capital solutions and strategic partnerships, meeting diverse needs across market cycles. With over $20 billion in assets under management, the team uniquely combines credit and equity expertise to deliver both financial and operational value beyond traditional providers. To learn more, visit (http://www.baincapital.com). Follow @BainCapital on LinkedIn and X (Twitter).

About Mayapada Healthcare Group
Mayapada Healthcare Group (PT Sejahteraraya Anugrahjaya Tbk.) (“SRAJ”) is a key business pillar of the Mayapada Group in the healthcare services sector. Mayapada Healthcare Group runs 7 (seven) hospitals with a total capacity of more than 1,000 beds, supported by more than 1,500 medical professionals who are experts in their fields. The seven hospitals of Mayapada Healthcare Group are Mayapada Hospital Tangerang, Mayapada Hospital Jakarta Selatan, Mayapada Hospital Bogor (BMC), Mayapada Hospital Kuningan, Mayapada Hospital Bandung and Mayapada Hospital Nusantara (IKN). Mayapada Hospital Jakarta Selatan obtained JCI accreditation in December 2024 while the other hospitals have the highest levels of accreditation domestically. Mayapada Healthcare Group operates several flagship services ‘Centers of Excellence’ including Tahir Neuroscience Center, Tahir Uronephrology Center, Cardiovascular Center, Gastrohepatology Center, Oncology Center, Orthopedic Center, Obstetrics & Gynecology Center, Pediatric Center, Internal Medicine and Pulmonology Center, Allergy-Immunology Center and the Autoimmune Center which is first and only service center in Indonesia. Mayapada Hospital Group has several projects in the pipeline and plans to operate more than 2,000 beds by 2027.

 Asia / China

 Zhen Trudy Wang

Categories: News

Tags:

EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million

EQT Life Science

Proceeds will be used to enable key late-stage clinical trial readouts for assets across several underserved neurological diseases with high unmet medical need.

EQT Life Sciences has led the extension, and joins a consortium of prominent global biotechnology investors.

The investment builds on EQT Life Sciences’ previous successful partnership with neurology-focused repeat entrepreneur and Noema Pharma CEO Ilise Lombardo, MD

EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in Noema Pharma (“the Company”). The clinical-stage biotech company headquartered in Basel, Switzerland is developing a pipeline of first-in-disease therapeutics that address central nervous system (CNS) disorders. The Series B extension brings the total capital raised in the round to CHF 130 million, including prior investments from Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus and UPMC Enterprises.

CNS disorders are a significant area of unmet medical need, affecting hundreds of millions of people worldwide who often face inadequate treatment options with limited effectiveness and significant side effects. Many of the conditions targeted by Noema Pharma have historically been difficult to treat due to their complex nature and the lack of effective therapies. By leveraging its diverse portfolio of neurological assets and innovative clinical pipeline, Noema Pharma is strongly positioned to address these debilitating disorders and provide much-needed hope and transformative solutions to patients living with these life-altering challenges. The Company’s portfolio includes four active Phase 2 trials, with key readouts from all studies anticipated in 2025.

Proceeds from the financing will drive the continued development of Noema Pharma’s clinical-stage assets, including its lead candidate basimglurant (NOE-101), a mGluR5 inhibitor currently in Phase 2 trials for severe pain in trigeminal neuralgia (TN) and seizures in tuberous sclerosis complex (TSC). Additionally, the Company is advancing gemlapodect (NOE-105), a PDE10a inhibitor in Phase 2 for Tourette syndrome and childhood onset fluency disorder (COFD or stuttering), as well as NOE-115, a broad-spectrum monoamine modulator in a Phase 2 trial for vasomotor symptoms and additional symptoms of menopause.

Ilise Lombardo, MD, CEO of Noema Pharma, stated: “We are thrilled to welcome EQT Life Sciences as a lead investor and to have Felice join our Board. Their support and expertise will be invaluable as we progress our clinical programs and strive to make a meaningful impact on patients’ lives.”

Felice Verduyn-van Weegen, Partner at EQT who is joining the Company’s Board of Directors, commented: “Noema Pharma’s innovative approach to CNS disorders aligns very well with our investment strategy and we are excited to support their late-stage clinical pipeline and transformative therapies. Having worked with Ilise Lombardo on a previous successful investment, her exceptional leadership as a repeat entrepreneur further reinforces our confidence in Noema’s potential to deliver meaningful impact to patients in need.”

Contact
EQT Press Office, press@eqtpartners.com

Categories: News

Tags:

Angitia Biopharmaceuticals Announces $120 Million Series C Financing

BainCapital
Source: Angitia Biopharmaceuticals
  • Financing led by Bain Capital Life Sciences with significant participation from existing and new investors
  • Proceeds will support the development of AGA2118, AGA2115, AGA111 and other pipeline assets for the treatment of serious musculoskeletal diseases
  • Norbert Riedel, Ph.D., will join the Board of Directors

WOODLAND HILLS, Calif. December 11, 2024 – Angitia Biopharmaceuticals (“Angitia” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced the closing of a $120 million Series C financing round. Bain Capital Life Sciences led the financing, with participation from new investor Janus Henderson and existing investors OrbiMed, 3H Health Investment, Yonghua Capital, Legend Capital, and Elikon Venture. Proceeds from the Series C will support Angitia’s robust pipeline of novel, differentiated treatments for serious musculoskeletal diseases.

“The broad support for Angitia in this financing validates the hard work of our team, the clinical progress of our programs, and the quality of our emerging data,” said Dr. David Ke, M.D., Chief Executive Officer of Angitia. “We express gratitude to our investors, new and returning, for their support in our journey to provide novel and effective treatments for patients with musculoskeletal disease, and we look forward to continuing to execute on developing these valuable medicines.”

Angitia is advancing AGA2118 and AGA2115, bispecific antibodies targeting sclerostin and DKK1, through clinical development for osteoporosis and osteogenesis imperfecta (OI), respectively. The two molecules represent the next generation of dual-acting treatments for skeletal disease, increasing bone formation and decreasing bone resorption. With these two bispecifics, Angitia seeks to promote stronger, more organized skeletal development in patients. The Company is also developing AGA111, a biologic to promote spinal fusion in patients with degenerative disc disease.

In conjunction with the financing, Dr. Norbert Riedel, Ph.D., will join the Company’s Board of Directors. A seasoned scientist and biopharmaceutical executive, he brings decades of leadership experience to Angitia. Dr. Riedel serves on the board of directors of Jazz Pharmaceuticals and Eton Pharmaceuticals and is Chairman of the Board of Alcyone Therapeutics. He recently completed his tenure on the board of Cerevel Therapeutics. Dr. Riedel previously founded Aptinyx, Inc. and served as CEO of Naurex, which was acquired by Allergan in 2015. He also held senior roles at Baxter International and Hoechst-Marion Roussel (now Sanofi). Dr. Riedel holds a diploma in biochemistry and a Ph.D. in biochemistry from the University of Frankfurt.

Angitia is enrolling patients in a Phase 2 study in postmenopausal women with AGA2118 (NCT06577935). AGA2115 is being developed for the treatment of OI and is currently in a first-in-human study (NCT06086613). AGA111 is being explored for use in patients undergoing lumbar interbody fusion in a Phase 3 study (NCT06115512).

About Angitia Biopharmaceuticals

Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. Angitia is currently studying 3 biologic product candidates in the clinic for the treatment of osteoporosis, osteogenesis imperfecta (OI), and spinal fusion. Leveraging the team’s extensive experience and scientific acumen in novel drug development, Angitia is committed to providing groundbreaking therapies to satisfy key unmet medical needs.

 Scott Lessne

Categories: News

Tags:

CompuGroup Medical enters into an investment agreement with CVC Capital Partners

CVC Capital Partners

CVC announces intention to launch a voluntary public tender offer to all free float shareholders

  • CVC to launch voluntary public tender offer for EUR 22.00, subsequent delisting envisaged
  • Significant premium of 51.1% to the 3M VWAP and 33.5% to closing price as of December 6, 2024 provides shareholders with opportunity to realize value immediately
  • Founding family Gotthardt and related shareholder Koop sign strategic partnership agreement with CVC and will retain majority stake
  • The road to CompuGroup Medical’s long-standing goal of improving healthcare worldwide through digitalization is being strengthened.
  • This partnership brings CGM customers further increased quality, highest safety and even stronger focus on innovation
  • CompuGroup Medical employees will remain part of a company that is even more ambitious, with a determined will to grow and a high level of innovation
  • Managing Directors, Supervisory Board and Administrative Board welcome strategic partnership with CVC and voluntary public tender offer

Koblenz – CompuGroup Medical SE & Co. KGaA, one of the world’s leading e-health providers, has been improving healthcare by digitizing medical care for more than 30 years. CompuGroup Medical’s software supports medical and organizational processes in doctors’ and dentist’s offices, pharmacies, laboratories, hospitals and social institutions daily. This provides medical professionals with more time for their patients and helpful medical information for the benefit of everyone in the healthcare system.

Today, CompuGroup Medical announced a strategic partnership agreement with CVC Capital Partners, one of the world’s leading private equity firms, and GT1 Vermögensverwaltung GmbH, CompuGroup Medical’s majority shareholder. The partnership with CVC will become effective if a holding company controlled by investment funds advised and managed by affiliates of CVC Capital Partners successfully completes a voluntary public tender offer for all outstanding shares of CompuGroup Medical at a price of EUR 22.00 per share in cash. The offer corresponds to a premium of 51.1% to the volume-weighted average price over the past three months.

The founding family Gotthardt and related shareholder Dr. Reinhard Koop, who together hold 50.1% of all shares, will retain their majority stake in CompuGroup Medical. CompuGroup Medical founder Frank Gotthardt will remain Chairman of the Administrative Board, while Prof. (apl.) Dr. med. Daniel Gotthardt continues as Chief Executive Officer and member of the Administrative Board.

The partnership with CVC is expected to support the long-term innovation and growth strategy of CompuGroup Medical. Together, CompuGroup Medical and CVC plan to drive innovation in healthcare for the benefit of patients and healthcare providers worldwide. The joint goal is to reliably empower medical professionals with next generation products and strong customer support.

Prof. (apl.) Dr. med. Daniel Gotthardt, CEO of CompuGroup Medical said: “At CompuGroup Medical, our highest priority is to provide customers – medical doctors, dentists, healthcare practitioners, hospitals and pharmacies and other healthcare providers – with the best possible solutions to advance healthcare. Based on innovative, data-based and AI-empowered solutions, we have the unique opportunity to add a new dimension to healthcare in the years to come. CVC’s extensive expertise in investments in the healthcare industry and software business will support us to deliver our strategy as planned. Our envisaged partnership will catalyze the next phase of innovation and expansion, for the benefit of our customers, and ultimately patients.”

Daniela Hommel, CFO of CompuGroup Medical, commented: “The Managing Directors welcome the envisaged strategic partnership with CVC due to their international network and deep industry expertise in the software and healthcare sectors. Partnering with CVC will allow us to take advantage of greater growth opportunities, such as investments in inorganic growth and increasing our focus on cloud-based products and AI-powered solutions. It will be particularly advantageous, when speed is of essence regarding financing. For our shareholders, the offer represents the opportunity to realize their investment at a premium of 51.1 % to the volume-weighted average price over the past three months.”

Frank Gotthardt, company founder and Chairman of the Administrative Board added: “The purpose of CompuGroup Medical remains unchanged: Nobody should suffer or die because at some point medical information was missing. Over decades, our customers and employees have appreciated the stability provided by a strong anchor shareholder. CompuGroup Medical will remain family-owned going forward. And I am convinced we have found the perfect partner to build on that strength to write the next successful chapter in our company history.”

Daniel Pindur, Managing Partner at CVC, said: “CompuGroup Medical has written an unparalleled success story over the past 30 years. There are only a handful of those founder-led stories in Germany. It has become a real European champion in digitization. We look forward to collaborating closely with the Gotthardt family and the team, leveraging CVC’s experience in strategic partnerships with founder-led family businesses. Together, we want to write the next chapter of healthcare.”

Can Toygar, Senior Managing Director at CVC, added: “In light of demographic changes and professional labor shortages, the healthcare market will need more digital solutions. CGM is an outstanding company, and uniquely positioned to transform healthcare in Europe, making it better and more efficient. Together, we will focus on investments in modern, data-based products and improving service quality for medical doctors, pharmacists and nursing staff.”

Offer Details

CVC intends to launch a voluntary public tender offer to all CompuGroup Medical free float shareholders for EUR 22.00 per share in cash. The offer corresponds to a premium of 51.1% to the volume-weighted average price over the past three months and will be subject to a minimum acceptance threshold of 17% and customary regulatory conditions, including antitrust clearance. Upon completion of the offer, and combined with founding family Gotthardt and related shareholder Dr. Koop, the strategic partners will hold at least 67% of all shares. The parties have agreed not to enter into a domination and/or profit and loss transfer agreement for a period of two years following the closing of the offer.

The Managing Directors, Supervisory Board and Administrative Board of CompuGroup Medical welcome the strategic partnership with CVC. CompuGroup Medical Management SE and the Supervisory Board intend to recommend the acceptance of the offer, subject to their review of the offer document. They will provide a reasoned statement pursuant to § 27 WpÜG after publication of the offer document by CVC. After completion of the tender offer, the management of CompuGroup Medical and CVC have agreed to take the company private by way of a delisting offer, which is intended in due course after closing of the tender offer.

The acceptance period is expected to begin by the end of December 2024. Closing of the transaction is expected in the first half of 2025. In accordance with the requirements of the German Securities Acquisition and Takeover Act, the offer document and other information in connection with CVC’s public tender offer will be made available on the following website after approval by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht): www.practice-public-offer.com

Download full press release

Categories: News

Tags:

EQT Life Sciences leads Series A funding round for maternal health company Nua Surgical

EQT Life Science

Irish maternal health company Nua Surgical secures €6.5M in Series A funding led by EQT Life Sciences

SteriCISION is the first self-retaining retractor designed specifically for Caesarean section (C-section) surgeries

Proceeds will be used for regulatory approval and commercialization of the SteriCISION C-section retractor

EQT Life Sciences is pleased to announce that the EQT Health Economics strategy has invested in Nua Surgical, an Irish medical device company innovating in maternal health. The €6.5 million Series A financing was led by EQT Life Sciences. The round was also supported by new investors Kidron Capital and the Texas Medical Center (TMC) Venture Fund and existing investors including Enterprise Ireland and business veterans from Ireland and the US. The proceeds will be used to drive the regulatory clearance and early commercialization of the company product, the SteriCISION C-Section Retractor. This innovative device is specifically designed to address the unique challenges of Caesarean-section (C-section) surgery.

C-sections are the most common major surgical procedure globally, with over 30 million performed each year. The SteriCISION C-Section Retractor is the only self-retaining surgical retractor specifically designed for the unique dynamics of C-section surgery. This ergonomically designed and patented device provides fast, adjustable, and safe retraction, enabling clinicians to deliver the baby, repair tissue, and, crucially, identify bleeds. As a single-use sterile device, it aims to reduce the risk factors that lead to surgical complications, benefiting the patient, the clinician, and the healthcare system. The new investment will support Nua Surgical’s next phase of development and the early commercialization of SteriCISION. This includes expanding the team, establishing manufacturing in Ireland, and meeting the regulatory requirements necessary to gain FDA clearance.

Barry McCann, CEO of Nua Surgical, commented, “Securing this Series A financing is a crucial milestone for Nua Surgical. It not only provides the capital needed to advance our product but also brings on board a group of experienced investors who share our vision for transforming maternal health. We are eager to leverage their expertise as we move towards commercializing SteriCISION.”

“Nua Surgical’s SteriCISION C-Section Retractor has the potential to significantly enhance outcomes for mothers undergoing C-section procedures,” said Anne Portwich, Partner at EQT. “We are excited to support the company’s journey towards market entry. This innovative device has the potential to improve the quality of care and reduce healthcare costs, making it a perfect fit for our EQT Health Economics strategy.”

With the closure of this round, Anne Portwich, Partner at EQT, and Anula Jayasuriya, Co-Founder of Kidron Capital, will join the Nua Surgical Board of Directors, while Gabrielle Guttman of TMC Venture Fund and Prashanthi Ramesh of EQT will serve as Board Observers.

Contact
EQT Press Office, press@eqtpartners.com

About

About EQT Life Sciences
EQT Life Sciences was formed in 2022 following the integration of LSP, a leading European life sciences venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs entrepreneurs who have ideas that could truly make a difference for patients. The team combines deep sector knowledge, analytical skills, and investment experience to provide the added value that entrepreneurs seek. For more information, go to eqtgroup.com/private-capital/life-sciences/

About Nua Surgical
Nua Surgical is a Galway-based medical company founded in 2019 by Barry McCann, Marie-Therese Maher and Padraig Maher. Since spinning out of the renowned BioInnovate Ireland programme at the University of Galway, Nua Surgical have become an Enterprise Ireland HPSU company and have received global accolades for their maternal health innovation. The company has developed the SteriCISION C-section Retractor, ergonomically designed to improve access and visualization to the uterus, reduce the risk of wound trauma and facilitate a safer surgery. The experienced founding team is bolstered with expert consultants and the recent appointment of Dr. Elizabeth Garner, global women’s health thought leader, as their board chair. For more information visit www.nuasurgical.com

 

 

Categories: News

Tags:

Arlington Capital Partners Acquires TEAM Technologies

Arlington

A leader in medical device manufacturing, TEAM Tech is focused on optimizing supply chains to ensure better and faster delivery of critical healthcare products

Washington, D.C. – November 25, 2024 – Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced it has acquired TEAM Technologies, Inc (“TEAM Tech”), a leading global manufacturer of essential healthcare products, from Clearlake Capital Group (“Clearlake”).

TEAM Technologies is a leading provider of specialized manufacturing and strategic supply chain solutions to blue-chip healthcare customers. The Company provides a broad array of end-to-end outsourced design and manufacturing services to medical device and pharmaceutical OEMs, with a growing specialty in advanced medical devices that are critical to the healthcare system. Through its comprehensive suite of vertically integrated processes, TEAM Tech enables customers to streamline their supply chains and reduce lead times in delivering critical products. TEAM Tech has approximately 1,000,000 square feet of manufacturing space across nine campuses in the U.S., Mexico, and Singapore.

“As the last five years have demonstrated, global supply chains are not nearly as fortified as they need to be, particularly in medical device manufacturing,” said Matt Altman, a Managing Partner at Arlington Capital Partners. “TEAM Tech is not only focused on providing the world’s leading healthcare OEMs with holistic solutions for all their design and manufacturing needs, but also on strengthening our healthcare supply chains to improve the delivery of these critical goods to end users.” Added Gordon Auduong, an Arlington Principal, “As one of the leading end-to-end providers in this sector, we look forward to working with TEAM Tech’s management team and building on its strong foundation to continue adding capabilities and customers, both through organic investment and strategic acquisitions.”

“The medical device manufacturing industry is incredibly complex, but we feel fortunate to partner with Arlington in our next chapter,” said Marshall White, CEO of TEAM Tech. “I have gotten to know Matt and the Arlington team well over the past several years and believe that with their 25 years of experience in this highly regulated sector they are best positioned to help us build on the successes we have achieved and accelerate our growth, both organically and through strategic acquisitions, to take our business to the next level.”

Arlington has an extensive track record of building leading companies in the highly regulated healthcare sector, focusing on businesses that save lives, improve the delivery of products and services, and reduce costs for patients and providers. Recent investments include Afton ScientificAVS BioMillstone Medical OutsourcingRiverpoint Medical and Grand River Aseptic Manufacturing.

Harris Williams served as financial advisor and Goodwin Procter LLP served as legal advisor to Arlington Capital Partners. R.W. Baird acted as financial advisor to TEAM Technologies. Kirkland & Ellis LLP and Massumi + Consoli provided legal counsel to TEAM Technologies and Clearlake.

 

About Arlington Capital Partners

Arlington Capital Partners is a Washington, D.C.-area private investment firm specializing in government-regulated industries. The firm partners with founders and management teams to build strategically important businesses in the healthcare, government services & technology, and aerospace & defense sectors. Since its inception in 1999, Arlington has invested in over 175 companies and is currently investing out of its $3.8 billion Fund VI. For more information, visit Arlington’s website at www.arlingtoncap.com and follow Arlington on LinkedIn.

 

About TEAM Tech

Headquartered in Morristown, TN, TEAM Technologies is a specialized end-to-end outsourced manufacturer of mission-critical medical devices. The Company has an extensive array of advanced and vertically integrated manufacturing solutions servicing top medical device and pharmaceutical OEMs. With its deep industry experience and reputation for the highest quality standards, TEAM Technologies leverages seamless, turnkey processes and innovation to drastically simplify its customers’ supply chains. For more information, visit teamtech.com.

Contact

Kelsey Clute

kclute@arlingtoncap.com

 

Ryan Fitzgibbons and Meredith Bishop

Pro-arlington@prosek.com

Categories: News

Tags:

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

GIMV

rehaneo, a leading provider of outpatient rehabilitation, aftercare, prevention, and occupational health management founded in 2020, welcomes Fremman Capital to its shareholder base. Fremman takes over the majority shareholding previously held by the European investment company Gimv. Founder and CEO Bruno Crone and co-founder and COO Christoph Dühr remain significantly invested in the company and continue their management roles.

Since its founding four years ago, during the peak of the COVID-19 pandemic, Gimv and the managing rehaneo shareholders Bruno Crone and Christoph Dühr have successfully built the company into one of the top three providers in the field of outpatient rehabilitation through a successful buy-and-build strategy. Since 2023, Dr. Alain Robbe-Grillet completes the management team as CFO.

To date, rehaneo has integrated 13 companies at 23 locations nationwide into the group, including some of the leading facilities in Germany. Recently, rehaneo also opened a completely new center in Göttingen.

The rehaneo group now employs over 1,000 staff who are dedicated to the care of more than 80,000 patients and customers annually. The range of services offered by the centers varies by location, from outpatient rehabilitation and rehab aftercare to physiotherapy and occupational therapy, as well as prevention and fitness. In addition to developing locations and the continuous growth of the group, the focus is primarily on the quality of services. This is ensured, among other things, by a medical board with renowned experts, including Prof. Dr. med. Thomas Wessinghage. rehaneo aims to further densify the care network and offer more people professional rehabilitation close to their homes.

Outpatient rehabilitation costs are significantly lower than inpatient stays, benefiting the healthcare system. Additionally, there is increasing demand from patients who want to stay in their familiar environment during rehabilitation. Together with Fremman, the management team intends to continue the successful growth strategy, accelerating M&A and consolidating further a very fragmented sector, to create a European leader.

Bruno Crone, Founder and CEO of the rehaneo group, declares: “We thank Gimv for their active support and the trustful cooperation from the beginning, which made it possible to become one of the leading quality providers in outpatient rehabilitation in such a short time. We are excited to start a new chapter of our success story with Fremman. Our focus will be on acquiring new outpatient rehab centers and the strategic development of existing facilities and the entire group.

Mirko Meyer-Schönherr and Max Schürenkrämer, Founding Partner and Managing Director at Fremman, add: “We are very impressed by the development of the rehaneo group so far and see great potential in the outpatient rehabilitation sector. We look forward to supporting the experienced and ambitious rehaneo management team in further developing the strategy of the group.

Philipp von Hammerstein and Lars Timmer, Partner and Principal at Gimv Healthcare, comment: “We are proud that together with rehaneo, we have built a leading company and competent partner in outpatient care in just four years, distinguished by high customer and patient satisfaction as well as high-quality standards.

The transaction is subject to approval by the German antitrust authorities and is expected to close in Q1 2025. This transaction will have a positive impact on our NAV at 30 September 2024, as will be published on 21 November next, of around EUR 1 per share. The realized return on this transaction substantially exceeds our long-term portfolio return target.

Categories: News

Tags:

819 Capital Partners and LIOF invest in I-Med Technology

819 Capital Partners

Deventer, November 19, 2024 – 819 Capital Partners and LIOF have invested in I-Med Technology (“I-Med”) in a substantial investment round. I-Med Technology develops and markets advanced head-mounted 3D imaging systems that provide real-time support, enhancing precision and efficiency in medical and dental procedures.

I-Med secures strategic investment to fuel 3D imaging expansion

I-Med Technology B.V., a cutting-edge medical technology company specializing in advanced 3D imaging systems for healthcare, announced today that it has secured an investment from 819 Capital Partners and LIOF, positioning the company for rapid growth and expanded market impact. Johan van de Ven, CEO of I-Med: “We are thrilled to partner with 819 Capital Partners and LIOF. Their support and investment enable us to move swiftly in bringing our technology to more clinicians and expanding our reach in the medical imaging market. This funding underscores the value of our innovation and allows us to continue pushing boundaries in medical visualization technology.”

Revolutionizing surgery: I-Med’s 3D head-mounted microscope enhances precision and safety

Founded in 2018 and headquartered at the Brightlands Health Campus in Maastricht, I-Med is committed to addressing critical challenges in surgical and dental procedures where precision and speed are essential. Vincent Graham, CTO at I-Med: “Traditional 2D imaging techniques, often displayed away from the surgical field, require clinicians to shift focus frequently, impacting procedural efficiency. I-Med’s Digital Head-mounted Microscope offers a breakthrough solution with Full HD, real-time 3D imaging, mixed realities, enhancing precision and quality while providing a safer and more seamless operating experience.” Jaap Heukelom, CCO at i-Med Technology, adds: “Moreover, the system represents a leap forward for medical training, education and remote support applications and offers a powerful platform for artificial intelligence applications that can assist the surgeon and dentist alike in their clinical practice”.

Investment driving societal impact in healthcare through improved patient outcomes

819 Capital Partners has invested in I-Med through 819 Evergreen Fund I, a fund committed to investments in deep-tech and med-tech ventures. Sven Kempers, director at 819: “Our investment in I-Med aligns with our goal of advancing promising technology. We have great confidence in I-Med’s technology and its growth potential.”

LIOF has invested in I-Med from their Participation Fund, a fund committed for newly started and medium-sized, innovative SMEs who want to grow. Willem van Esch, investment manager at LIOF: “We see the potential in I-Med’s 3D imaging systems to redefine surgical precision and enhance patient care. Our support will help accelerate their impact across the healthcare sector, making advanced imaging more accessible and transforming the future of medical procedures.”

About I-Med Technology B.V.

I-Med Technology B.V. is a medical technology company based in Maastricht dedicated to advancing real-time, mixed realities, 3D imaging solutions through head-mounted systems designed to support precise medical and dental interventions. With its unique, MDD and CE certified, DHM platform, I-Med empowers healthcare professionals with enhanced visualization capabilities that promote improved procedural outcomes and patient care. More information: www.i-medtech.nl

About 819 Capital Partners

819 Capital Partners is an investment firm managing multiple funds with targeted investment strategies. 819 Evergreen Fund takes minority stakes in early-stage deep-tech and med-tech startups, while 819 Private Equity Fund acquires controlling stakes in mature firms within the leisure, IT, and healthcare industries. The open-ended structure of their funds allows for long-term investments with flexible exit timelines. The firm focuses on sectors like healthcare, technology, and leisure, addressing societal challenges such as aging populations.

About LIOF

LIOF is the regional development agency for Limburg and supports innovative entrepreneurs with advice, network and financing. LIOF is available for every start-up, scale-up and small and medium-sized business (SME) with an innovative idea, a business plan or a financing request and for (foreign) entrepreneurs who want to establish themselves in Limburg. LIOF also helps with cross-border cooperation and international trade. Together with entrepreneurs and partners, LIOF is working towards a smarter, more sustainable and healthier Limburg by focusing on the transitions energy, circularity, health and digitalization.

Categories: News

Tags:

Stonepeak Completes Acquisition of Arvida

Stonepeak

NEW YORK & AUCKLAND, NEW ZEALAND – November 19, 2024 – Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets, today announced that it has completed its acquisition of Arvida Group Limited (“Arvida” or the “Company”) (NZX: ARV), one of New Zealand’s largest retirement and aged care providers.

“As one of the leading and most well-regarded retirement village operators in New Zealand, we believe Arvida has a bright future ahead and is well positioned to effectively serve the region’s growing aging population as a privately held entity,” said Darren Keogh, Senior Managing Director at Stonepeak. “We are excited to have closed this transaction and look forward to partnering closely with the Arvida team as the company enters this next chapter.”

“Today marks a transformational day for Arvida, and I am optimistic about the opportunities ahead,” said Jeremy Nicoll, Chief Executive at Arvida. “Stonepeak is aligned with our values and commitment to our employees, residents, and community, and we look forward to leveraging their extensive operational expertise as we execute on our strategy and mission of helping New Zealanders live a truly fulfilling life as they age.”

About Stonepeak

Stonepeak is a leading alternative investment firm specializing in infrastructure and real assets with approximately $70 billion of assets under management. Through its investment in defensive, hard-asset businesses globally, Stonepeak aims to create value for its investors and portfolio companies, with a focus on downside protection and strong risk-adjusted returns. Stonepeak, as sponsor of private equity and credit investment vehicles, provides capital, operational support, and committed partnership to grow investments in its target sectors, which include communications, energy and energy transition, transport and logistics, and real estate. Stonepeak is headquartered in New York with offices in Houston, London, Hong Kong, Seoul, Singapore, Sydney, Tokyo, and Abu Dhabi. For more information, please visit www.stonepeak.com.

About Arvida

Arvida is one of New Zealand’s largest aged care providers owning and operating 35 retirement villages located nationally. Each village operates independently under a corporate structure that supports village operations to ensure quality and consistency of service. Arvida provides a range of living and lifestyle options from independent living to full rest home, hospital and dementia-level care.

Arvida’s growth strategy includes the targeted development of new villages in areas that are supported by a strong demographic and economic profile and acquisition of quality villages that meet strict acquisition criteria as well as the development of additional facilities at existing villages.

Website: www.arvida.co.nz

Contacts

Stonepeak
Kate Beers / Maya Brounstein
corporatecomms@stonepeak.com
+1 (646) 540-5225

Jack Gordon
jack.gordon@sodali.com
+61 478 060 362

Arvida
Geoff Senescall, Senescall Akers
senescall@senescallakers.co.nz
+64 21 481 234

Categories: News

Tags: